Date	Headline
Jul 29, 2019	Provectus Names Frank Akers, PhD to Company’s Strategic Advisory Board
Jul 15, 2019	Provectus Receives Notice of Allowance for Fourth Cancer Combination Therapy Patent from the United States Patent and Trademark Office
Jul 08, 2019	Provectus Provides Update on GI Tumor Program for Investigational Cancer Drug PV-10
Jun 03, 2019	Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019
Jun 03, 2019	Provectus Announces Preliminary Results from Phase 1 Trial of PV-10 for Treatment of Metastatic Neuroendocrine Tumors at ASCO 2019

Our Contact Form	Mailing Address
Telephone: +1 (866) 594-5999 Fax: +1 (866) 998-0005 info@pvct.com	Provectus Biopharmaceuticals, Inc. 10025 Investment Drive, Suite 250 Knoxville, TN 37932
Investor Relations	Media Relations
Provectus Biopharmaceuticals, Inc. Email: investorrelations@pvct.com Phone: +1 (866) 594-5999 x1	Provectus Biopharmaceuticals, Inc. E-mail: mediarelations@pvct.com Phone: +1 (866) 594-5999 x4
Transfer Agent
(i.e. stockholder records, transfer, change of address, etc.) Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, NY 11717 E-mail: shareholder@broadridge.com Telephone: +1 (877) 830-4936 Fax: +1 (215) 553-5402

Filing Date	Form Type	Description	View
Aug 08, 2019	10-Q	Quarterly report	html pdf xbrl
May 13, 2019	10-Q	Quarterly report	html pdf xbrl
May 09, 2019	10-K/A	Annual report (Amendment)	html pdf
Mar 07, 2019	10-K	Annual report	html pdf xbrl
Nov 08, 2018	10-Q	Quarterly report	html pdf xbrl

Company Overview